Rekvina Labs Ltd () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

51.0 (-91.11%) Volume

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

41.30%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 0.00% and Operating profit at 0% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at 0 times

Flat results in Mar 26

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 23 Cr ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.00

Return on Equity

0.00%

Price to Book

-22.58

Revenue and Profits:

Net Sales:

1 Cr

(Quarterly Results - Mar 2026)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

16.28%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Rekvina Labs for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

Financial Results For Quarter Ended & Year Ended On March 31 2026.

21-May-2026 | Source : BSE

Standalone Audited Financial Results for the Quarter ended & Year ended on March 31 2026 along with statement of Assets & Liabilities Cash Flow statement & unmodified Audit Report.

Board Meeting Outcome for Outcome Of Board Meeting Held On 21St May 2026

21-May-2026 | Source : BSE

Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation 2015 we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended and Year ended on March 31 2026 along with Assets & Liability Statement & Cash Flow Statement with Independent Auditor Report 2. Declaration of Auditor Report with unmodified Opinion pursuant to Reg 33 (3)(d) of Listing Regulations signed by Mr. Amit Shah Director of the Company.

Board Meeting Intimation for Consider And Approve Financial Result For The QTR 4

18-May-2026 | Source : BSE

Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve Financial Result for the Quarter and Year ended 31.03.2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

Rekvina Labs Ltd has announced 5:10 stock split, ex-date: 30 Apr 14

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.22

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-1.49%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-22.13

EV to EBIT

-22.36

EV to EBITDA

-22.36

EV to Capital Employed

-22.36

EV to Sales

17.60

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Surbhit Mukesh Shah (15.22%)

Highest Public shareholder

Viralkumar Tribhovandas Patel (4.388%)

Individual Investors Holdings

45.88%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 105.71% vs 75.00% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 50.00% vs -300.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.72",
          "val2": "0.35",
          "chgp": "105.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.06",
          "val2": "-0.12",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.06",
          "val2": "-0.12",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8.33%",
          "val2": "-34.29%",
          "chgp": "25.96%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Rekvina Labs"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Rekvina Labs"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -78.57% vs -75.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.27",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.25",
          "val2": "-0.14",
          "chgp": "-78.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.25",
          "val2": "-0.14",
          "chgp": "-78.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-19.69%",
          "val2": "0.00%",
          "chgp": "-19.69%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.72

0.35

105.71%

Operating Profit (PBDIT) excl Other Income

-0.06

-0.12

50.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.06

-0.12

50.00%

Operating Profit Margin (Excl OI)

-8.33%

-34.29%

25.96%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 105.71% vs 75.00% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 50.00% vs -300.00% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1.27

0.00

Operating Profit (PBDIT) excl Other Income

-0.25

-0.14

-78.57%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.25

-0.14

-78.57%

Operating Profit Margin (Excl OI)

-19.69%

0.00%

-19.69%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is -78.57% vs -75.00% in Mar 2025

All Annual Results

Company CV

About

Company Coordinates

Company Details

Tel:

Registrar Details

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."